A detailed history of Susquehanna International Group, LLP transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 43,370 shares of COGT stock, worth $340,020. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,370
Previous 103,200 57.97%
Holding current value
$340,020
Previous $869,000 46.14%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.24 - $11.48 $492,999 - $686,848
-59,830 Reduced 57.97%
43,370 $468,000
Q2 2024

Aug 15, 2024

BUY
$6.01 - $9.04 $61,704 - $92,813
10,267 Added 11.05%
103,200 $869,000
Q1 2024

May 07, 2024

BUY
$4.38 - $9.02 $22,710 - $46,768
5,185 Added 5.91%
92,933 $624,000
Q4 2023

Feb 14, 2024

BUY
$4.06 - $10.08 $225,411 - $559,641
55,520 Added 172.27%
87,748 $515,000
Q3 2023

Nov 14, 2023

BUY
$9.69 - $13.34 $112,336 - $154,650
11,593 Added 56.18%
32,228 $314,000
Q2 2023

Aug 11, 2023

SELL
$9.85 - $13.24 $937,473 - $1.26 Million
-95,175 Reduced 82.18%
20,635 $244,000
Q1 2023

May 16, 2023

BUY
$10.04 - $15.5 $851,050 - $1.31 Million
84,766 Added 273.05%
115,810 $1.25 Million
Q4 2022

Feb 14, 2023

SELL
$10.65 - $14.84 $473,477 - $659,756
-44,458 Reduced 58.88%
31,044 $358,000
Q3 2022

Nov 14, 2022

BUY
$9.39 - $16.99 $377,074 - $682,267
40,157 Added 113.61%
75,502 $1.13 Million
Q2 2022

Aug 15, 2022

BUY
$3.92 - $9.73 $138,552 - $343,906
35,345 New
35,345 $319,000
Q2 2021

Aug 11, 2021

SELL
$7.82 - $9.3 $2.22 Million - $2.64 Million
-284,250 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$7.47 - $12.34 $2.12 Million - $3.51 Million
284,250 New
284,250 $2.5 Million

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $516M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.